Key Developments: Becton Dickinson and Co (BDX)
101.12USD
20 May 2013
$-0.66 (-0.65%)
$101.78
$101.61
$102.02
$100.96
798,981
1,134,827
$102.42
$71.56
Latest Key Developments (Source: Significant Developments)
Corning Inc Gets U.S. Approval To Buy Becton Dickinson And Co's Assets-Reuters
Reuters reported that Corning Inc has won U.S. approval to buy a division of Becton Dickinson & Co that makes specialized labware, but must help Sigma-Aldrich Co (SIAL.O) enter that market. The value of the deal was given as $730 million when it was announced in April. Full Article
Becton Dickinson And Co And Lab21 Collaborate To Develop New Oncology Assays On BD MAX Platform
Becton Dickinson And Co and Lab21 announced that they will collaborate to develop oncology assays for the BD MAX fully automated, bench-top molecular system. Under the terms of the collaboration, Lab21 will develop polymerase chain reaction-based assays on the BD MAX platform for a series of oncology markers. BD will be responsible for manufacturing and commercializing the tests worldwide. The first two assays will be designed to detect mutations in the KRAS and BRAF genes. These initial assays were selected because of their current importance in optimizing the management of cancer patients. The agreement also includes the development of nucleic acid extraction procedures from formalin-fixed paraffin-embedded tissue. The collaboration will develop BD's offering in personalized cancer diagnostics on the BD MAX system. Full Article
Becton Dickinson And Co's Receives 510(k) Clearance From U.S. Food And Drug Administration
BD Diagnostics, a segment of Becton Dickinson and Company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD VeritorTM System for Rapid Detection of respiratory syncytial virus (RSV). This new product is cleared for use in clinical settings. Full Article
Becton Dickinson And Co Announces Chief Financial Officer Transition
Becton Dickinson And Co announced that David V. Elkins, Executive Vice President and Chief Financial Officer (CFO), has informed the Company of his plans to pursue an entrepreneurial opportunity at Round Rock Research, LLC, a technology licensing company, serving as its CFO. He will leave BD in November following the Company's release of full fiscal year 2012 results on November 7, 2012. BD's Board of Directors intends to commence a search for a successor to Mr. Elkins. Full Article
Becton Dickinson And Co Reaffirms FY 2012 EPS Guidance
Becton Dickinson And Co announced that for fiscal 2012, it continues to expect reported diluted earnings per share (EPS) from continuing operations between $5.33 and $5.38. According to I/B/E/S Estimates, analysts are expecting the Company to report EPS of $5.36 for fiscal 2012. Full Article
Hologic Inc's Gen-Probe Announces Favorable Ruling In Litigation With Becton, Dickinson and Company
Hologic Inc announced a favorable ruling in its patent infringement litigation filed by its subsidiary, Gen-Probe (formerly Gen-Probe Incorporated), against Becton, Dickinson and Company (BD). In a decision dated September 28, 2012, the Honorable Roger T. Benitez, United States District Judge for the Southern District of California, granted Gen-Probe's summary judgment motions of direct infringement, ruling that the use of BD's ProbeTec Qx CT/GC (chlamydia and gonorrhea) assays on the BD VIPER System with XTR Technology, and the use of BD's GBS assays on the BD MAX System, infringe three of Gen-Probe's patents covering automated nucleic acid testing. The Court also granted summary judgment that BD's specimen collection products, used in conjunction with its ProbeTec Qx CT/GC assays, infringe another Gen-Probe patent covering penetrable caps. The Court denied BD's summary judgment motion to dismiss Gen-Probe's infringement claims based on an alleged lack of standing to sue, as well as BD's summary judgment motions seeking to invalidate the asserted patents. The Court found that BD did not infringe a fourth automation patent and a second penetrable cap patent. A jury trial on the remaining issues is scheduled to begin on December 4, 2012. Full Article
Becton Dickinson And Co Acquires Sirigen Group Limited
Becton Dickinson And Co announced that it has acquired Sirigen Group Limited, a developer of polymer dyes that are used in flow cytometry and can be applied to other technologies. The financial terms of the acquisition were not disclosed. Full Article
Becton, Dickinson and Company Sees FY 2012 Revenue Guidance Near Low End Of Prior Range; Lowers FY 2012 EPS Guidance
Becton, Dickinson and Company announced that for fiscal 2012, it expects revenue growth to be about 1% versus previously disclosed guidance of 1%-2%. This reflects the anticipated effects of unfavorable currency translation. On a currency-neutral basis, the Company is raising the lower end of previously disclosed guidance of 3%-4% to about 4%. The Company expects reported diluted earnings per share (EPS) from continuing operations to be between $5.33-$5.38. This reflects the reclassification of the Discovery Labware unit as discontinued operations and the anticipated effects of unfavorable currency translation. On a currency-neutral basis, the Company reaffirms previously disclosed diluted earnings per share growth guidance of 4%-5%, which includes the estimated impact of recently announced agreement to acquire Safety Syringes, Inc. The Company reported revenue of $7.8 billion in fiscal 2011. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $7.9 billion and EPS of $5.70 for fiscal 2012. Full Article
Becton, Dickinson and Company Declares Dividend
Becton, Dickinson and Company announced that it has declared a quarterly dividend of $0.45 per common share, payable on September 28, 2012 to holders of record on September 7, 2012. The indicated annual dividend rate is $1.80 per share. Full Article
Becton, Dickinson and Company Announces Agreement To Acquire Safety Syringes, Inc.
Becton, Dickinson and Company announced that it has entered into a definitive agreement to acquire Safety Syringes, Inc., a privately held California-based company that specializes in the development of anti-needlestick devices for prefilled syringes. The acquisition, which is subject to the satisfaction of customary closing conditions, including regulatory approvals, is expected to close by the end of BD's fiscal year 2012. The financial terms of the agreement were not disclosed. Full Article
UPDATE 2-Becton Dickinson earnings helped by early flu season
* Adjusted operating fiscal Q1 EPS $1.53 vs Street view of $1.24
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
